Study provides first potential targets for effective immune responses against COVID-19. The findings provide essential information for vaccine design against SARS-CoV-2.
Historical data from Flu Watch about other coronaviruses reveals they appear to have a seasonal pattern, with peaks occurring during winter. Only small amounts of other coronavirus infections were transmitted during the summer. The findings support the hypothesis that COVID-19 may have lower levels of transmission during the summer, but this may reverse during the winter months if there is still a large, susceptible population.
Study warns of the potentially serious adverse effects of prescribing hydroxychloroquine and azithromycin for the treatment of COVID-19. Some of the potential side effects include cardiac arrhythmias, hypoglycemia, and neuropsychiatric effects.
Researchers are making progress in developing potential vaccines for coronavirus infections. While a vaccine for COVID-19 might be over a year away from market, researchers are looking ahead to attempt to prevent future outbreaks.
New coronavirus model finds case spread is concave, meaning the impact of one more infected person diminishes as more people become infected.
Researchers have developed a novel antibody strategy to prevent the association between a harmless protein and a disease mediator that could lead to sepsis, and ultimately death. The findings could help to prevent sepsis induced by COVID-19 infections.
Researchers have identified a potential new drug target for COVID-19. The scientists mapped the anatomical structures of two critical SARS-CoV-2 proteins in the nsp10/nsp16 complex. If a drug can be developed to inhibit nsp10/nsp16, researchers believe the immune system should be able to detect the infection and eradicate it faster.
The COVID causing SARS-CoV-2 protein interacts with alpha-synuclein, speeding up the formation of amyloid plaques, a new study reports.
Recent stressful experiences, such as the loss of a loved one or economic insecurity are strong predictors as to whether a person hospitalized for COVID-19 will experience symptoms of long COVID a year later.
Researchers isolated live SARS-CoV-2, the virus responsible for COVID-19, from the feces of patients who died as a result of coronavirus infection. Antigens to the virus were also found in post-mortem gastrointestinal surface cells. Isolating the live virus from fecal matter indicates evidence of the infectious virus in feces is a common manifestation of COVID-19. Researchers also found SARS-CoV-2 RNA on surfaces and bedding samples in hotel rooms used by two presymptomatic people who were later diagnosed with COVID-19.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Multisystem inflammatory syndrome in children, a Kawasaki-like disease that appears to result from COVID-19 infections, damages the heart to such an extent that children will need lifelong monitoring and interventions.
